MYPROSTATESCORE 2.0
Clear Results. Confident Decision.
MPS2 is a urine test designed to predict the presence of clinically significant prostate cancer by analyzing a comprehensive array of 18 unique gene transcripts. Our algorithm has been developed to optimize diagnostic accuracy and provide clinical flexibility, allowing MPS2 to be run as a biomarker-only test or inclusive of clinical risk factors, depending on provider preference. Receive individualized reports with results tailored to unique patient and clinical context.
Stay Up To Date
Resources
Industry news, men’s health information, and expert prostate cancer and risk assessment research.
Lynx Dx Announces Medicare Coverage for MyProstateScore 2.0, Marking a Major Milestone in Prostate Cancer Risk Assessment
Lynx Dx is proud to announce that MyProstateScore 2.0 (MPS2) has been approved for coverage from Medicare.
Yes, Prostate Cancer May Affect Sexual Performance. No, It’s Not Necessarily Permanent.
Having a prostatectomy often affects a man’s libido and ability to get an erection, but recovery is possible through penile rehabilitation, medication or devices.
5 Common Questions About Prostate Cancer, Answered
Information regarding prostate cancer symptoms, treatment options and their side effects, prognosis and survival rate, and how to detect it early.